A national collaborative study of the in vitro activity of oral cephalosporins and loracarbef (LY 163892)

R. A.V. Benn, C. J. Fernandes, G. R. Nimmo, Australian Group for the Study of Antimicrobial Resistance, J. Bell, J. Andrew, H. Pruul, J. Bull

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A national collaborative study involving the laboratories of 17 Australian hospitals examined the in vitro activity of loracarbef, cefaclor, cephalexin, amoxycillin and amoxycillin/clavulanate against 2661 recently isolated common bacterial pathogens. Loracarbef was the most active agent against Escherichia coli (MIC90 = 1 mg/l) and had activity comparable to other agents against Klebsiella pneumoniae and Proteus mirabilis. Like the oral cephalosporins, it had no activity against species of Enterobacter and Serratia. β-lactamase-producing Staphylococcus aureus and Haemophilus influenzae were moderately sensitive to loracarbef (MIC90 = 8 mg/l for both species). Streptococcus pneumoniae was moderately sensitive to loracarbef (MIC90 = 2 mg/l) but strains which were insensitive to penicillin were often highly resistant.

Original languageEnglish
Pages (from-to)79-83
Number of pages5
JournalPathology
Volume29
Issue number1
DOIs
Publication statusPublished - 1997
Externally publishedYes

Keywords

  • Cefaclor
  • Cephalexin
  • Loracarbef

Fingerprint Dive into the research topics of 'A national collaborative study of the in vitro activity of oral cephalosporins and loracarbef (LY 163892)'. Together they form a unique fingerprint.

  • Cite this

    Benn, R. A. V., Fernandes, C. J., Nimmo, G. R., Australian Group for the Study of Antimicrobial Resistance, Bell, J., Andrew, J., Pruul, H., & Bull, J. (1997). A national collaborative study of the in vitro activity of oral cephalosporins and loracarbef (LY 163892). Pathology, 29(1), 79-83. https://doi.org/10.1080/00313029700169604